{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:45:27Z","timestamp":1792683927936,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.rpth.2026.106920","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:50:16Z","timestamp":1787849416000},"page":"106920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A miniaturized chemiluminescent thrombin generation assay to assess the effect of APCC in persons with hemophilia A with inhibitors: an observational study"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8448-9151","authenticated-orcid":false,"given":"Aernoud P.","family":"Bavinck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora J.","family":"Steeghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"van Engelshoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerissa M.M.","family":"Coolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia J.","family":"van de Ridder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Baran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Windyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia E.M.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"van \u2019t Veer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waander L.","family":"van Heerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 6","key":"10.1016\/j.rpth.2026.106920_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/jth.13298","article-title":"When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH","volume":"14","author":"Fischer","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106920_bib4","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106920_bib5","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM197407252910402","article-title":"Activated prothrombin concentrate for patients with factor VIII inhibitors","volume":"291","author":"Kurczynski","year":"1974","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106920_bib6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2516.2009.02012.x","article-title":"FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre","volume":"15","author":"Smejkal","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1055\/s-0038-1656122","article-title":"Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors","volume":"77","author":"Negrier","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/20406207231184323","article-title":"Real-world data in patients with congenital hemophilia and inhibitors: final data from the FEIBA global outcome (FEIBA GO) study","volume":"14","author":"Ettingshausen","year":"2023","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.rpth.2026.106920_bib9","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2516.2011.02693.x","article-title":"Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey","volume":"18","author":"Z\u00fclfikar","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib10","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1056\/NEJMoa1104435","article-title":"Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors","volume":"365","author":"Leissinger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106920_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/hae.12873","article-title":"Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA in prophylactic therapy","volume":"22","author":"V\u00e1radi","year":"2016","journal-title":"Haemophilia"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.106920_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2004.00934.x","article-title":"FEIBA: mode of action","volume":"10","author":"Turecek","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib13","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1111\/j.1538-7836.2012.04793.x","article-title":"Mechanisms and monitoring of bypassing agent therapy","volume":"10","author":"Hoffman","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib14","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferri\u00e8re","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106920_bib15","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/hae.14933","article-title":"Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: review of the real-world evidence","volume":"30","author":"Kenet","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib16","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s12185-014-1572-4","article-title":"Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor","volume":"99","author":"Ogiwara","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2026.106920_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2516.2008.01931.x","article-title":"Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors","volume":"15","author":"Berntorp","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0049-3848(81)90319-4","article-title":"Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor","volume":"22","author":"Fukui","year":"1981","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106920_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.0954-6820.1978.tb14910.x","article-title":"Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII","volume":"203","author":"Stenbjerg","year":"1978","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.rpth.2026.106920_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0002-9343(88)80353-X","article-title":"Acute myocardial infarction during treatment with an activated prothrombin complex concentrate in a patient with factor VIII deficiency and a factor VIII inhibitor","volume":"85","author":"Chavin","year":"1988","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2026.106920_bib21","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2007.01594.x","article-title":"Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues","volume":"14","author":"Aledort","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1046\/j.1365-2516.2002.00532.x","article-title":"Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events","volume":"8","author":"Ehrlich","year":"2002","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib23","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.106920_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2025.102926","article-title":"Activated prothrombin complex concentrate in patients receiving emicizumab prophylaxis: from evidence to clinical practice","volume":"9","author":"Sidonio","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib25","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1055\/s-0043-1777766","article-title":"Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia a with factor VIII inhibitors","volume":"8","author":"Castaman","year":"2024","journal-title":"TH Open"},{"key":"10.1016\/j.rpth.2026.106920_bib26","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1055\/s-0029-1245106","article-title":"Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents","volume":"35","author":"Ananyeva","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106920_bib27","first-page":"527","article-title":"Factor eight inhibitor bypass activity (FEIBA) in the management of bleeds in hemophilia patients with high-titer inhibitors","volume":"3","author":"Tj\u00f8nnfjord","year":"2007","journal-title":"Vasc Health Risk Manag"},{"issue":"suppl 6","key":"10.1016\/j.rpth.2026.106920_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2516.2006.01366.x","article-title":"Basic aspects of bypassing agents","volume":"12","author":"Negrier","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib29","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1046\/j.1538-7836.2003.00450.x","article-title":"Monitoring the bioavailability of FEIBA with a thrombin generation assay","volume":"1","author":"V\u00e1radi","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib30","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1182\/blood-2010-06-291906","article-title":"Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery","volume":"116","author":"Dargaud","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106920_bib31","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.thromres.2014.12.015","article-title":"Large external quality assessment survey on thrombin generation with CAT: further evidence for the usefulness of normalisation with an external reference plasma","volume":"136","author":"Perrin","year":"2015","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106920_bib32","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2022.100018","article-title":"Thrombin generation and implications for hemophilia therapies: a narrative review","volume":"7","author":"Sidonio","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2025.117469","article-title":"Novel microfluidic device for factor VIII quantification by chemiluminescence in hemophilia A patients","volume":"282","author":"Steeghs","year":"2025","journal-title":"Biosens Bioelectron"},{"key":"10.1016\/j.rpth.2026.106920_bib35","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.jtha.2026.01.021","article-title":"A chemiluminescent microfluidic thrombin generation assay for real-time monitoring in patient plasma","volume":"24","author":"Steeghs","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/10760296211021156","article-title":"Investigation of the optimal dose aPCC in reversing the effect of factor Xa inhibitors-an in vitro study","volume":"27","author":"Schultz","year":"2021","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106920_bib37","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.106920_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109045","article-title":"Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: a comprehensive assessment","volume":"240","author":"Haisma","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106920_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.2041-210x.2012.00261.x","article-title":"A general and simple method for obtaining R2 from generalized linear mixed-effects models","volume":"4","author":"Nakagawa","year":"2012","journal-title":"Methods Ecol Evol"},{"key":"10.1016\/j.rpth.2026.106920_bib40","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/j.1538-7836.2010.03773.x","article-title":"Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels","volume":"8","author":"Lavigne-Lissalde","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib41","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1538-7836.2007.02448.x","article-title":"Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia","volume":"5","author":"Castoldi","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1538-7933.2003.00617.x","article-title":"Impact of procoagulant concentration on rate, peak and total thrombin generation in a model system","volume":"2","author":"Allen","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-69415-y","article-title":"Deciphering the coagulation profile through the dynamics of thrombin activity","volume":"10","author":"de Laat-Kremers","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.rpth.2026.106920_bib44","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.14203","article-title":"In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents","volume":"16","author":"Hartmann","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/hae.70087","article-title":"Coagulation potential in haemostatic agents concomitant with low concentration of emicizumab under severe haemophilia A state","volume":"31","author":"Kawasaki","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib46","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000071637","article-title":"Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay","volume":"33","author":"Turecek","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.rpth.2026.106920_bib47","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1111\/j.1365-2516.2009.02132.x","article-title":"Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A","volume":"16","author":"Klintman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib48","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/hae.12309","article-title":"Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors","volume":"20","author":"Luna-Z\u00e1izar","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2516.2009.02116.x","article-title":"Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series","volume":"16","author":"Ettingshausen","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib50","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jtha.2023.09.017","article-title":"Thrombin generation on vascular cells in the presence of factor VIII and\/or emicizumab","volume":"22","author":"Atsou","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib51","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/hae.14213","article-title":"Comparison of bypassing agents in patients on emicizumab using global hemostasis assays","volume":"27","author":"Kizilocak","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib52","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/hae.14684","article-title":"Safety of FEIBA and emicizumab (SAFE): dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab","volume":"29","author":"Kizilocak","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106920_bib53","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib54","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/rth2.12238","article-title":"Thrombin generation measurement using the ST genesia thrombin generation system in a cohort of healthy adults: normal values and variability","volume":"3","author":"Calzavarini","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib55","series-title":"Williams Hematology","first-page":"2018","author":"Kaushansky","year":"2021"},{"key":"10.1016\/j.rpth.2026.106920_bib56","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0049-3848(00)00389-3","article-title":"Effects of \u03b12-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma","volume":"101","author":"Cvirn","year":"2001","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106920_bib57","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1182\/blood.V78.9.2299.2299","article-title":"Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children","volume":"78","author":"Mitchell","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106920_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1309\/AJCP6AY4HTRAAJFQ","article-title":"Optimization of plasma fluorogenic thrombin-generation assays","volume":"132","author":"Chandler","year":"2009","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.rpth.2026.106920_bib59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2007.06663.x","article-title":"Thrombin generation: the functional role of alpha-2-macroglobulin and influence of developmental haemostasis","volume":"138","author":"Ignjatovic","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106920_bib60","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/jth.12798","article-title":"The balance of pro- and anticoagulant processes underlying thrombin generation","volume":"13","author":"Kremers","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2026.103386","article-title":"Duplication of the prothrombin gene is associated with a significant increase in thrombin generation","volume":"10","author":"Siegemund","year":"2026","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12800","article-title":"Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes","volume":"6","author":"Mathews","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106920_bib63","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1111\/jth.14863","article-title":"Towards standardization of thrombin generation assays: inventory of thrombin generation methods based on results of an international society of thrombosis and haemostasis scientific standardization committee survey","volume":"18","author":"de Laat-Kremers","year":"2020","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926035788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:25:03Z","timestamp":1792682703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926035788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":63,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2475037926035788"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106920","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A miniaturized chemiluminescent thrombin generation assay to assess the effect of APCC in persons with hemophilia A with inhibitors: an observational study","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106920"}}